Introduction {#s1}
============

Bronchiectasis is a chronic respiratory disease characterised by progressive bronchial dilatation. To date, no therapy has been licensed for its treatment. Geographic regions illustrate preponderance for particular aetiologies, *e.g.* post-tuberculous disease in countries of endemic infection \[[@C1]\]. Incipient infection in bronchiectasis incites deleterious host inflammatory responses and disease progression. A "vicious cycle" of impaired mucociliary clearance, recurrent infection and chronic inflammation, with established links to bacteria, leads to progressive disease; however, the role of fungi is poorly understood.

The pulmonary microbiome and its association with chronic respiratory disease is an emerging area of research. Culture-independent airway sequencing has revealed novel associations between the airway microbiome and lung disease \[[@C2]\]. To date, most airway microbiome studies have a bacterial focus, an approach that provides disease insight into pathogenesis and prognosis \[[@C3], [@C4]\]. In contrast, however, sequencing of the fungal microbiome (the mycobiome) has lagged behind and is applied in relatively few studies, and to the best of our knowledge, none in bronchiectasis \[[@C5]\].

Fungal spores are environmentally ubiquitous and hence their inhalation is an inevitable consequence of breathing \[[@C6]\]. While prompt mucociliary and phagocytic clearance occurs in the healthy lung, anatomically abnormal and immunocompromised airways such as in bronchiectasis are at higher risk of fungal acquisition, colonisation and potential disease \[[@C6]\]. Our group and others have performed extensive work characterising fungi in cystic fibrosis (CF)-related bronchiectasis where they colonise and act as pathogens associated with poorer clinical outcome \[[@C7]--[@C10]\].

Fungi, particularly *Aspergillus* spp., cause a range of pulmonary consequences, including allergic, chronic and/or invasive disease \[[@C11], [@C12]\]. An overzealous host response to *Aspergillus*, for instance, is clinically important in severe asthma with fungal sensitisation, chronic obstructive pulmonary disease (COPD) and CF \[[@C13]--[@C15]\]. The role of fungi in bronchiectasis not due to CF is, however, less well defined. *Aspergillus* sensitisation and/or allergic bronchopulmonary aspergillosis (ABPA) is a cause (∼10%) and, importantly, a consequence of bronchiectasis \[[@C6], [@C10], [@C16]\]. The role of the mycobiome in bronchiectasis is yet to be comprehensively investigated, and its importance and relevance is clearly highlighted as a priority research area in this field \[[@C17]\].

We characterise for the first time the mycobiome in bronchiectasis, assessing its clinical relevance in two geographically distinct cohorts from the CAMEB study, encompassing four Asian sites across Singapore/Kuala Lumpur and a single European site in Dundee.

Materials and methods {#s2}
=====================

Study population {#s2a}
----------------

Patients with stable bronchiectasis were recruited across three countries as part of the CAMEB study, a cross-sectional Cohort of Asian and Matched European Bronchiectasis. Recruitment included three sites in Singapore (Singapore General Hospital, Changi General Hospital and Tan Tock Seng Hospital (n=124)), one Malaysian site (UKM Medical Centre, Kuala Lumpur (n=14)), and an age-, sex- and disease severity-matched group from a single European site (Ninewells Hospital, Dundee, UK (n=100)), and was conducted between March 2016 and July 2017. Full details on patient inclusion and exclusion criteria, nondiseased controls, and the CAMEB population are provided in the [supplementary material](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.00766-2018.figures-only#fig-data-supplementary-materials). Clinical characteristics, bronchiectasis aetiology and patient demographics are shown in [table 1](#TB1){ref-type="table"}. The study was approved by the institutional review boards of all participating institutes and all patients gave written informed consent to participate. Further details are given in the [supplementary material](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.00766-2018.figures-only#fig-data-supplementary-materials).

###### 

Demographics of the study population including nondiseased (healthy) controls and stable bronchiectasis patients comprising Asian and European matched cohorts

                                           **Nondiseased controls**  **Bronchiectasis patients**   **Bronchiectasis patients SG/KL**   **Matched cohorts**   
  --------------------------------------- -------------------------- ----------------------------- ----------------------------------- --------------------- -------------
  **Subjects**                                        10             238                           138                                 100                   100
  **Age years**                                  37 (30--49)         68 (64--71)                   65 (58--73)                         65 (58--74)           69 (64--76)
  **Sex**                                                                                                                                                    
   Female                                           4 (40)           130 (55)                      77 (55)                             59 (59)               53 (53)
   Male                                             6 (60)           108 (45)                      61 (45)                             41 (41)               47 (47)
  **Aetiology**                                                                                                                                              
   Idiopathic                                                        145 (61)                      85 (62)                             63 (63)               60 (60)
   Post-infection                                                    56 (23.5)                     43 (31)                             27 (27)               27 (27)
   Other                                                             37 (15.5)                     10 (7)                              10 (10)               13 (13)
  **Smoking status**                                                                                                                                         
   Never-smoker                                                      170 (70)                      108 (78)                            80 (80)               62 (62)
   Current smoker                                                    11 (5)                        7 (5)                               4 (4)                 4 (4)
   Ex-smoker                                                         57 (25)                       23 (17)                             16 (16)               34 (34)
  **BSI status**                                                                                                                                             
   Severe                                                            147 (62)                      84 (61)                             63 (63)               63 (63)
   Moderate                                                          71 (30)                       45 (33)                             26 (26)               26 (26)
   Mild                                                              20 (8)                        9 (6)                               11 (11)               11 (11)
  **BSI score**                                                      9 (6--13)                     10 (7--14)                          10 (7--14)            9 (6--12)
  **BMI kg·m^−2^**                               24 (22--24)         21 (18--27)                   19 (17--22)                         19 (17--22)           27 (22--31)
  **MRC dyspnoea score**                                                                                                                                     
   1--3                                                              200 (84)                      121 (88)                            90 (90)               79 (79)
   4                                                                 26 (11)                       10 (7)                              6 (6)                 16 (16)
   5                                                                 12 (5)                        7 (5)                               4 (4)                 5 (5)
  **FEV~1~ % pred**                                                  74 (54--87)                   69 (51--84)                         69 (52--84)           76 (57--96)
  **Radiological severity**                                                                                                                                  
   1--2 lobes involved                                               106 (45)                      62 (45)                             43 (43)               44 (44)
   ≥3 lobes involved                                                 132 (55)                      76 (55)                             57 (57)               56 (56)
  **Exacerbations in previous year**                                                                                                                         
   0                                                                 84 (35)                       69 (50)                             44 (44)               15 (15)
   1--2                                                              82 (35)                       51 (37)                             41 (41)               31 (31)
   ≥3                                                                72 (30)                       18 (13)                             15 (15)               54 (54)
  **Hospital admissions before study**                                                                                                                       
   Yes                                                               88 (37)                       63 (46)                             43 (43)               25 (25)
   No                                                                150 (63)                      75 (54)                             57 (57)               75 (75)
  **Colonisation with other organisms**                                                                                                                      
   Yes                                                               127 (53)                      60 (43)                             44 (44)               67 (67)
   No                                                                111 (47)                      78 (57)                             56 (56)               33 (33)
  ***Pseudomonas* colonisation**                                                                                                                             
   Yes                                                               23 (10)                       18 (13)                             15 (15)               5 (5)
   No                                                                215 (90)                      120 (87)                            85 (85)               95 (95)
  **Bronchodilator use**                                                                                                                                     
   Yes                                                               107 (45)                      58 (42)                             39 (39)               49 (49)
   No                                                                131 (55)                      80 (58)                             61 (61)               51 (51)
  **Inhaled corticosteroids**                                                                                                                                
   Yes                                                               80 (34)                       21 (15)                             14 (14)               59 (59)
   No                                                                158 (66)                      117 (85)                            86 (86)               41 (41)
  **Mucolytics**                                                                                                                                             
   Yes                                                               118 (50)                      60 (44)                             45 (45)               13 (13)
   No                                                                120 (50)                      78 (56)                             55 (55)               87 (87)
  **Long-term antibiotics**                                                                                                                                  
   Yes                                                               48 (20)                       22 (16)                             14 (14)               26 (26)
   No                                                                190 (80)                      116 (84)                            86 (86)               74 (74)

Data are presented as n, median (interquartile range) or n (%). SG/KL: Singapore/Kuala Lumpur; BSI: Bronchiectasis Severity Index; BMI: body mass index; MRC: Medical Research Council; FEV~1~: forced expiratory volume in 1 s. Patients in the matched cohorts were matched on age, sex and disease severity according to the BSI. The variables defining the composite BSI score, including BMI, shortness of breath (MRC) dyspnoea score, FEV~1~ % pred, radiological severity, number of exacerbations in the preceding year defined by established consensus \[18\], hospitalisations in the preceding year, microbial colonisation with other organisms and colonisation by *Pseudomonas aeruginosa*, are also reported.

Methods {#s2b}
-------

Full details on clinical data and specimen collection, statistical analysis, and molecular methods, including mycobiome analyses, sputum quantitative PCR (qPCR) detection of fungi and immunological bioassays, are provided in the [supplementary material](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.00766-2018.figures-only#fig-data-supplementary-materials).

Results {#s3}
=======

The pulmonary mycobiome in bronchiectasis is distinct {#s3a}
-----------------------------------------------------

Culture-independent analysis of the pulmonary mycobiome in bronchiectasis reveals that Ascomycota dominate the airway at the phylum level (p\<0.01, Mann--Whitney U-test) ([figure 1](#F1){ref-type="fig"}). Fungal diversity was significantly lower in bronchiectasis, as measured by the number of identified taxa (p\<0.01) and the Shannon diversity index (p\<0.05, Mann--Whitney U-test) ([figure 1](#F1){ref-type="fig"}). Limitations of fungal internally transcribed spacer (ITS) databases may account for the lower classification percentages observed (95.3%) compared with bacteria, where genus-level operational taxonomic unit classification of ∼99% can be achieved \[[@C19]\]. Despite Ascomycota dominating overall mycobiome profiles, a significant number of bronchiectasis patients (49% (n=116)) harboured some degree of airway Basidiomycota. 10% (n=23) had Basidiomycota making up at least a quarter of their overall profile, while 4% (n=9) exhibited Basidiomycota-dominant profiles ([figure 2a](#F2){ref-type="fig"}). *Candida*, *Saccharomyces* and *Penicillium* were the most frequently detected genera in both groups, while differentially abundant, bronchiectasis-associated genera included *Aspergillus*, *Cryptococcus*, *Clavispora*, *Botrytis* and *Alternaria* ([figures 2b](#F2){ref-type="fig"} and 3a).

![The pulmonary mycobiome in stable bronchiectasis: mirrored Sankey plots illustrating the relative abundance of read classification by taxonomic rank from phylum (centre; blue) to genus level (margins; red). Nondiseased (healthy) controls (n=10) are compared with patients with stable bronchiectasis (n=238). Central coloured bars demonstrate phylum-level abundance of Ascomycota (yellow) *versus* Basidiomycota (blue) between the cohorts. Cohort-specific fungal genera are indicated in bold.](ERJ-00766-2018.01){#F1}

![The pulmonary mycobiome in stable bronchiectasis: a) individual patient phylum-level classification of the pulmonary mycobiome in stable bronchiectasis (n=238) illustrating the relative abundance of Ascomycota *versus* Basidiomycota for individual patients, and b) percent prevalence of the top fungal genera (present at \>1% relative abundance) in nondiseased (healthy) controls (n=10) and patients with stable bronchiectasis (n=238).](ERJ-00766-2018.02){#F2}

In the design of the CAMEB study, n=100 Asian patients (Singapore/Kuala Lumpur) were matched individually to patients from a European cohort (Dundee) by age, sex and total Bronchiectasis Severity Index (BSI) score ([table 1](#TB1){ref-type="table"}). This allowed assessment of findings in two geographically distinct cohorts as well as providing insight into potential regional differences in the bronchiectasis mycobiome. Geographic variation in mycobiome signature was detected ([figure 3a](#F3){ref-type="fig"}). Patients from Singapore/Kuala Lumpur exhibited significant and higher average relative abundances of *Simplicillium*, *Trichosporon* and *Aspergillus*, while patients from Dundee were distinguished by higher abundances of *Wickerhamomyces*, *Clavispora* and *Cryptococcus* (p\<0.05) following assessment of group differences using metastats statistical analysis \[[@C20]\]. *Candida*, by far the most frequently observed fungal genera, was observed across both cohorts at equal frequency, while patients from Dundee exhibited higher *Saccharomyces*, *Penicillium*, *Cryptococcus*, *Clavispora* and *Botrytis* in particular. The only fungal genus in the top 10 with higher prevalence in Singapore/Kuala Lumpur was *Aspergillus*, although this was detected at all the sampled sites ([figure 3b](#F3){ref-type="fig"}). Given our identification of *Aspergillus* as an exclusive bronchiectasis-associated fungal genus with high airway abundance and its established pathogenic role in other chronic respiratory diseases \[[@C10], [@C12], [@C13], [@C15]\], we pursued it for further investigation.

![The pulmonary mycobiome differs between Singapore/Kuala Lumpur (SG/KL) and Dundee cohorts of stable bronchiectasis. a) Genus-level classification of the pulmonary mycobiome in nondiseased (n=10), stable bronchiectasis (n=238), and matched SG/KL (n=100) and Dundee (n=100) cohorts. The relative abundance of identified taxa is colour-coded. b) Percent prevalence of observed fungal genera (present at \>1% relative abundance) in matched bronchiectasis cohorts from SG/KL (n=100) and Dundee (n=100). Significant differences in prevalence between cohorts are indicated. \*\*: p\<0.01; \*\*\*: p\<0.001.](ERJ-00766-2018.03){#F3}

*Aspergillus fumigatus* and *Aspergillus terreus* are identified in bronchiectasis and associate with exacerbations {#s3b}
-------------------------------------------------------------------------------------------------------------------

We next further characterised the presence of specific *Aspergillus* species in the airway by qPCR using established protocols published by our group and others \[[@C7], [@C21]\]. We assessed four major *Aspergillus* species (*A. fumigatus*, *A. terreus*, *A. flavus* and *A. niger*) and found that nondiseased individuals had no detectable airway *Aspergillus*, in agreement with our mycobiome analysis ([figure 4a](#F4){ref-type="fig"}). In contrast, high proportions of bronchiectasis patients (from all sites) had detectable *A. fumigatus* and/or *A. terreus*, with no patient demonstrating *A. flavus* or *A. niger* ([figure 4a](#F4){ref-type="fig"}). Interestingly, similar proportions of those recruited from an Asian site had either *A. fumigatus* and/or *A. terreus*, while patients from Dundee demonstrated higher *A. terreus* ([figure 4a](#F4){ref-type="fig"}), which associates with increased exacerbations ([figure 4b](#F4){ref-type="fig"}). Importantly, significant numbers of patients (40% (n=96)) harboured both species concurrently. Of these, an equal distribution between groups recruited from Singapore/Kuala Lumpur and Dundee was observed (44% *versus* 52%; p=0.22) ([figure 4c](#F4){ref-type="fig"}). Patients from Singapore/Kuala Lumpur were equally likely to have none, either or both species in their airway, in contrast to patients from Dundee who exhibited a higher likelihood for *A. terreus* ([figure 4c](#F4){ref-type="fig"}). More exacerbations were seen in patients with *A. terreus* alone or where both species were present compared with those without any fungi or *A. fumigatus* alone ([figure 4d](#F4){ref-type="fig"}).

![Identification of specific airway *Aspergillus* species and their association with exacerbations in bronchiectasis. qPCR: quantitative PCR; SG/KL: Singapore/Kuala Lumpur; ND: nondiseased; BR: bronchiectasis. a) qPCR-based screening for the presence of the major specific *Aspergillus* species (*A. fumigatus*, *A. terreus*, *A. flavus* and *A. niger*) in ND (healthy) controls (n=10) and stable BR (n=238). b) Exacerbations for the year preceding study recruitment in patients with qPCR-detectable *A. fumigatus* (left) and *A. terreus* (right). c) Classification of qPCR-detectable *Aspergillus* species by percentage of the total bronchiectasis patient cohort (n=238). Patients are classified as having no detectable species (n=39), *A. fumigatus* only (n=26), *A. terreus* only (n=78) or both *A. fumigatus* and *A. terreus* (n=95). d) Exacerbations for the year preceding study recruitment in patients with no detectable species, *A. fumigatus* only, *A. terreus* only or both *A. fumigatus* and *A. terreus*. Median number of exacerbations per group is indicated. [ns]{.smallcaps}: nonsignificant; \*: p\<0.05; \*\*: p\<0.01; \*\*\*: p\<0.001.](ERJ-00766-2018.04){#F4}

Quantification of *A. fumigatus* to *A. terreus* conidial burden ratio and associated exacerbations {#s3c}
---------------------------------------------------------------------------------------------------

We next quantified *A. fumigatus* and *A. terreus* conidial burden using established protocols published by our group \[[@C7]\]. Based on the number of conidia per gram of sputum, we then classified the detected loads as low (\<500 conidia·g^−1^ sputum), intermediate (500--2000 conidia·g^−1^ sputum) or high (\>2000 conidia·g^−1^ sputum). Measured conidial burden varied among *Aspergillus*-positive patients, and was comparable between patients recruited from Singapore/Kuala Lumpur and Dundee ([figure 5a](#F5){ref-type="fig"}). Interestingly, where patients harboured both species concurrently, their proportionality varied: patients from sites in Singapore/Kuala Lumpur exhibited higher proportions of *A. fumigatus* (median 69% of conidial load), while the Dundee cohort had a higher *A. terreus* burden (median 89% of total conidial load) ([figure 5b](#F5){ref-type="fig"}). This agrees with our earlier observation of regional variation, where cohorts in Singapore/Kuala Lumpur tended toward more *A. fumigatus* and the Dundee cohort greater *A. terreus* either when the fungi exist alone or together. When patients were grouped by detectable *Aspergillus* species and accompanying conidial burden (using high load as cut-off), a significant association existed between high concurrent conidial burdens of both *Aspergillus* species and greater exacerbations ([figure 5c](#F5){ref-type="fig"}). Specifically, however, when a high conidial burden of *A. terreus* was identified, either alone or in combination with *A. fumigatus*, significantly more exacerbations also occurred ([figure 5c](#F5){ref-type="fig"}).

![Quantification of airway *Aspergillus* conidial burden and its association with exacerbations in bronchiectasis (n=238). SG/KL: Singapore/Kuala Lumpur. a) Conidial burden per gram of sputum was quantified for *A. fumigatus* and *A. terreus*, respectively, and classified according to load as low (\<500 conidia·g^−1^ sputum), intermediate ("Int."; 500--2000 conidia·g^−1^ sputum) or high (\>2000 conidia·g^−1^ sputum). Conidial load categories are illustrated according to fungal airway status as *A. fumigatus* only, *A. terreus* only or the presence of both species. b) Scatter plot of *A. fumigatus* (*x*-axis) and *A. terreus* (*y*-axis) conidial load in stable bronchiectasis. Patients with single and both species are indicated. Patients with both species are classified by their relative *A. fumigatus* and *A. terreus* burdens into low burden of both ("LL"), low burden of *A. fumigatus* and high burden of *A. terreus* ("LH"), high burden of *A. fumigatus* and low burden of *A. terreus* ("HL"), and high burden of both ("HH"). Dotted lines indicate cut-off levels for a high conidial burden (\>2000 conidia·g^−1^ sputum). c) Exacerbations for the year preceding study recruitment in bronchiectasis patients with detectable conidial burdens of both *A. fumigatus* and *A. terreus* as classified as in (b). Median number of exacerbations per group is indicated and Benjamini--Hochberg adjusted p-values for all groups compared with "None" are shown. \*: p=0.01; \*\*: p=0.006.](ERJ-00766-2018.05){#F5}

A high frequency of clinically relevant *Aspergillus*-associated disease occurs in bronchiectasis {#s3d}
-------------------------------------------------------------------------------------------------

Prior work from our group and others highlights the association of *Aspergillus*-associated disease (aspergillosis) with adverse clinical outcomes across a range of chronic respiratory diseases \[[@C7], [@C13], [@C22]\]. Given the high frequencies of *Aspergillus* detected, we next evaluated the occurrence of aspergillosis and its clinical relevance in bronchiectasis. To do this, we used a modified immunological classification system developed for CF ([supplementary table E4](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.00766-2018.figures-only#fig-data-supplementary-materials)) \[[@C14]\]. In addition to the criteria described by B[axter]{.smallcaps} *et al.* \[[@C14]\], our modified version includes incorporation of potential *A. terreus*-associated disease (by inclusion of *A. terreus* specific IgE and qPCR) along with other minor modifications detailed in [supplementary table E4](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.00766-2018.figures-only#fig-data-supplementary-materials). Of note, although total IgE was measured, it was not used in our classification of patients because it has been described that ABPA may occur at IgE concentrations below the described cut-offs in the established criteria \[[@C23]\]. Patients were grouped into the following five categories: nondiseased (ND), *Aspergillus-*colonised (AC), *Aspergillus-*sensitised (AS), serological ABPA (sABPA) and suspected chronic pulmonary aspergillosis (sCPA). Significant numbers in the CAMEB cohort met criteria for an *Aspergillus*-associated disease state (ND 1.7%, AC 3.4%, AS 76.5%, sABPA 18.1% and sCPA 0.3%) ([figure 6](#F6){ref-type="fig"}). Measured total serum IgE, *Aspergillus* specific IgG and sputum galactomannan varied between patient groups ([supplementary figure E1](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.00766-2018.figures-only#fig-data-supplementary-materials)). Specific IgE against crude antigens of *A. fumigatus* and *A. terreus,* respectively, was highest in AS (0.77 and 0.57 kU·L^−1^) and sABPA (0.92 and 0.93 kU·L^−1^) (p\<0.001) ([figure 6a](#F6){ref-type="fig"} and b). TARC (thymus and activation regulated chemokine), previously identified as a marker of CF-ABPA, was also assessed \[[@C24]\]. We found TARC to be a poor indicator of AS and/or sABPA in bronchiectasis, with high false-negative rates in both groups ([figure 6c](#F6){ref-type="fig"}). Additionally, false positives were also observed in a small number of ND patients ([figure 6c](#F6){ref-type="fig"}). Patients with sABPA exhibited significantly more exacerbations, poorer pulmonary function and the severest disease compared with other groups ([figure 6d](#F6){ref-type="fig"} and f). AS was associated with greater exacerbations, while AC portended toward more exacerbations with preserved pulmonary function and less severe disease ([figure 6d](#F6){ref-type="fig"} and f). The AC, AS and sABPA states therefore appear to exist along an increasing continuum of disease severity. Only a single patient met criteria for sCPA, precluding further analysis of this group. *Aspergillus*-associated disease in bronchiectasis is therefore frequent, variable and clinically relevant, including in patients appearing clinically stable (a characteristic inclusion criteria for our study).

![Immunological classification reveals high frequencies of aspergillosis in stable bronchiectasis and an association of serological allergic bronchopulmonary aspergillosis (sABPA) with greater exacerbations, poorer pulmonary function and more severe disease. SG/KL: Singapore/Kuala Lumpur; ND: nondiseased; AC: *Aspergillus-*colonised; AS: *Aspergillus-*sensitised; sCPA: suspected chronic pulmonary aspergillosis; TARC: thymus and activation regulated chemokine; FEV~1~: forced expiratory volume in 1 s; BSI: Bronchiectasis Severity Index. a, b) Measured levels of specific IgE responses to a) *A. fumigatus* and b) *A. terreus*, where aspergillosis is classified immunologically as ND (n=4), AC (n=8), AS (n=182), sABPA (n=43) and sCPA (n=1) ([supplementary table E4](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.00766-2018.figures-only#fig-data-supplementary-materials)). c) TARC, a proposed ABPA marker in cystic fibrosis \[[@C24]\], was assessed according to the same classification. Dashed lines show respective cut-offs indicating a positive test for each marker (specific IgE 0.35 kU·L^−1^; TARC 386 pg·mL^−1^). d) Exacerbations for the year preceding study recruitment, e) pulmonary function (FEV~1~ % pred) and f) disease severity (BSI) were assessed according to immunological aspergillosis class. Mean values are indicated except for exacerbations and BSI, where median values are shown. \*: p\<0.05; \*\*: p\<0.01; \*\*\*: p\<0.001.](ERJ-00766-2018.06){#F6}

*Aspergillus*-associated disease in bronchiectasis has distinct mycobiome profiles {#s3e}
----------------------------------------------------------------------------------

As high frequencies of *Aspergillus*-associated disease were observed in bronchiectasis based on our modified classification system, we next assessed for the presence of distinct taxonomic profiles that may associate with four of the five clinical states: ND, AC, AS and sABPA, excluding sCPA because this group contained only a single patient. Although unsupervised β diversity analysis revealed three distinct mycobiome groups ([supplementary figure E3](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.00766-2018.figures-only#fig-data-supplementary-materials)), their association with clinical phenotype was not evident. We therefore adopted a supervised strategy comparing mycobiome profiles between our identified immunological classes. Each clinical state revealed mycobiome profiles characterised by a combination of varying fungal genera ([figure 7](#F7){ref-type="fig"}). The ND group exhibited apparent high abundance of *Phellinus*, *Magnusiomyces* and *Phlebia*, with lower relative abundance of *Saccharomyces*, *Aspergillus* and *Penicillium* ([figure 7a](#F7){ref-type="fig"}). These latter three genera, however, increased in their relative abundance across a spectrum from ND to AC, AS and sABPA ([figure 7](#F7){ref-type="fig"} and [supplementary table E5](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.00766-2018.figures-only#fig-data-supplementary-materials)). The genera *Cryptococcus* and *Clavispora* followed similar and comparable spectra, with increasing relative abundance from AC, AS to sABPA. *Mycosphaerella* and *Botrytis* were present only in diseased states without a specific pattern ([figure 7b](#F7){ref-type="fig"} and d). Other characteristic fungal genera included *Trichosporon* and *Cladosporium* in the AC state, and *Wickerhamomyces* and *Alternaria* in the AS and sABPA states ([figure 7b](#F7){ref-type="fig"}). Importantly, the relative abundance of *Aspergillus* detected from mycobiome profiles was in agreement with our qPCR-based quantification of conidial burden for *A. fumigatus* and *A. terreus* across all disease categories, with greater exacerbations noted in AS and sABPA ([figure 7](#F7){ref-type="fig"}). Mycobiome profiles unique to each *Aspergillus*-associated disease state are therefore potentially useful for future bronchiectasis studies that focus on the diagnosis and endo-phenotyping of fungal disease.

![Pulmonary mycobiome profiles illustrate specific taxa-associated patterns according to immunological classification of aspergillosis in stable bronchiectasis. ND: nondiseased; AC: *Aspergillus-*colonised; AS: *Aspergillus-*sensitised; sABPA: serological allergic bronchopulmonary aspergillosis. a) ND (n=4), b) AC (n=8), c) AS (n=182) and d) sABPA (n=43) mycobiome profiles illustrate the different composition by relative abundance of reads classified to genus level, with the b) AC, c) AS and d) sABPA states exhibiting increased exacerbations and higher conidial load. Only a single patient had sCPA and therefore data is not shown. Mycobiome profiles are represented by pie charts with colour coding according to the taxonomic legend. Adjacent colour-coded log-scaled bar charts detail the observed taxa patterns in each immunological patient class (formal statistical assessment is provided in [supplementary table E5](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.00766-2018.figures-only#fig-data-supplementary-materials)). Exacerbations in the preceding year (*y*-axis) are plotted against *Aspergillus* conidial load (*x*-axis) and colour-coded according to quantitative PCR detection status of *Aspergillus* species into *A. fumigatus* alone, *A. terreus* alone, presence of both or none. Patients are further classified according to their individual conidial load as negative ("Neg."; no detected conidia·g^−1^ sputum), low (\<500 conidia·g^−1^ sputum), intermediate ("Int."; 500--2000 conidia·g^−1^ sputum) or high (\>2000 conidia·g^−1^ sputum).](ERJ-00766-2018.07){#F7}

Discussion {#s4}
==========

We describe the first, culture-independent analysis of the pulmonary mycobiome performed to date in bronchiectasis and, to the best of our knowledge, the first such respiratory study to meticulously match geographically distinct patient cohorts allowing us to assess potential regional variation in the mycobiome. By applying high-throughput 18S--28S ITS sequencing and other molecular techniques, we delineated the mycobiome constituents and their associated clinically relevant states. Our analysis identified *Aspergillus* as a major fungal genus in bronchiectasis, similar to that described in other chronic respiratory diseases \[[@C6], [@C12]\]. An interesting observation was the prevalence of specific *Aspergillus* species characterising our Singapore/Kuala Lumpur and Dundee cohorts, with *A. fumigatus* and *A. terreus* most frequently detected within each respective group, the latter associated to exacerbations. Further patient stratification into groups including AC, AS and sABPA states revealed high occurrences of clinically significant disease, even in "stable" patients, and the existence of distinct mycobiome profiles of discriminant taxa for each group.

Changes to regional lung growth conditions create a conducive environment for colonisation and infection by pathogenic microbes \[[@C2]\]. Given the gross anatomical distortion characteristic of bronchiectasis, it is therefore unsurprising that microbial differences are observed when compared with nondiseased states. The chronic bronchial insult coupled to anatomical distortion, compromised mucociliary clearance, sustained neutrophilic response and recurrent infection all favour the growth of pathogenic fungi and their ensuing clinical consequences in bronchiectasis \[[@C6], [@C25]\].

As observed in this and other studies, the airway mycobiome is dominated by Ascomycota \[[@C26]\]. Ascomycota-dominant profiles are characteristic of bronchiectasis, although an important minority have high airway Basidiomycota. Basidiospores are environmentally more abundant and smaller than ascospores, explaining their airway presence \[[@C27]\]. Compared with Ascomycota, which includes the established respiratory pathogens *Aspergillus* and *Candida*, the specific role of Basidiomycota in bronchiectasis is unclear. Notably, pathogenic Basidiomycota including *Cryptococcus*, *Schizophyllum*, *Phellinus*, *Ceriporia* and *Trichosporon* were all detected in our work \[[@C28]\]. *Cryptococcus* is significantly elevated in bronchiectasis, an observation previously documented that now warrants further investigation \[[@C29]\]. The existence of pulmonary Basidiomycota might reflect dynamic trafficking of "rare biosphere" fungi ("immigration and elimination"), suggestive of a healthier respiratory state rather than the sustained fungal outgrowth and unfavourable environment associated with Ascomycota \[[@C2], [@C5]\]. The cross-sectional design of our study, however, precluded longitudinal assessment of the stability and transiency of the mycobiome over time, a key consideration for future work.

Bronchiectasis-associated fungal genera include *Aspergillus*, *Issatchenkia*, *Wickerhamomyces* and *Simplicillium*. Where dedicated species-specific qPCR for *Aspergillus* was performed, only *A. fumigatus* and *A. terreus* were identifiable in bronchiectasis. Interestingly, *A. fumigatus* had a preponderance within the Asian cohorts from Singapore/Kuala Lumpur, while *A. terreus* exhibited higher prevalence and burden in patients from Dundee. Even in patients with both species, geographic origin dictated which proportionally dominated. Our patients were stringently matched for age, sex and disease severity in order to confront the heterogeneity that plagues bronchiectasis research and allowed us to better assess potential geographic variation. Studies of additional cohorts from Europe and Asia will be required to determine if these are truly geographical differences or reflect differences in patient selection or referral patterns at the participating sites. These geographic phenotypes were accompanied by differences in lung mycobiome profiles: *Penicillium*, *Clavispora* and *Cryptococcus* had markedly higher frequency in patients from Dundee, while Basidiomycota genera *Phlebia*, *Trichosporon*, *Ceriporia*, *Phellinus*, *Schizophyllum*, *Psathyrella* and *Peniophora* were exclusive to patients from Singapore/Kuala Lumpur who exhibited higher overall Basidiomycota. Our identified differences may reflect a myriad of regionally variable factors such as contrasting atmospheric conditions between temperate and tropical climates including temperature and humidity, each documented to affect fungi \[[@C30], [@C31]\]. Interestingly, our identified geographic variation of *A. terreus* predominance in Dundee occurred despite low reported UK prevalence rates of this fungus, suggestive of enrichment in the bronchiectasis population \[[@C32]\]. CF-related bronchiectasis also associates with *A. terreus* and an unidentified "environmental exposure" of likely relevance in our Dundee cohort is ascribed to this species \[[@C33], [@C34]\]. Other key geographic factors to consider include dietary preferences, genetics, air quality and/or lifestyle, all influences on acquisition and persistence of microbes including fungi \[[@C35]\]. Interestingly, the marked body mass index difference between our "matched" cohorts raises questions about potential differences in gut microbiomes that in turn may associate with the airway mycobiome given the emerging lung--gut axis relationship, an area of increasing relevance to respiratory health \[[@C36]\]. Other confounders to consider include regional differences in pharmacological prescribing and their consequent implications for the mycobiome. These are important considerations given differences between our Dundee and Singapore/Kuala Lumpur cohorts in terms of inhaled corticosteroids, long-term prophylactic antibiotics (greater in Dundee) and mucolytic use (greater in Singapore/Kuala Lumpur) ([table 1](#TB1){ref-type="table"}), all features of potential influence on mycobiome composition that warrant further study. While our findings could be peculiar to Dundee, Singapore and Malaysia, generalisability is supported by data showing that Dundee patients are similar and data generated in Scotland has been generalisable across more than 10 European cohorts in recent analyses \[[@C37], [@C38]\].

Our group and others have previously investigated the role of *Aspergillus*-associated disease in CF-related bronchiectasis, although focused work in non-CF bronchiectasis is lacking \[[@C7], [@C35], [@C39]--[@C41]\]. Importantly, however, E[veraerts]{.smallcaps} *et al.* \[[@C22]\] assessed the occurrence of *A. fumigatus* sensitisation in COPD and, when detectable, associated it with a high risk for bronchiectasis. These data support the role for *Aspergillus* as a bronchiectasis pathogen either as a cause or consequence. Our data further corroborate such associations with high observable specific IgE levels to *A. fumigatus* and *A. terreus*. Using a modified immunological classification, adapted from CF, we describe high rates of AS and sABPA disease states in the CAMEB cohort, outlining its clinical relevance even in patients appearing clinically stable \[[@C14]\]. TARC, a proposed marker of CF-ABPA, was found to have poor sensitivity and specificity when applied to the CAMEB cohort, illustrating difficulties in translating findings from CF to non-CF bronchiectasis \[[@C24]\]. Each of our classified clinical states is accompanied by a distinct mycobiome pattern suggestive of mechanistic links necessitating future studies.

A potential role for *A. terreus* in bronchiectasis is a novel finding of this work. When compared with *A. fumigatus*, *A. terreus* is less studied. It is, however, noted for colonising the CF lung, is capable of causing ABPA and associates with opportunistic infections \[[@C42]--[@C44]\]. Its resistance to polyene antifungals confers survival advantages in the host compared with *A. fumigatus* \[[@C45], [@C46]\]. Although *A. terreus* conidia are rapidly phagocytosed through their recognition by dectin-1 and mannose receptors, they exhibit increased macrophage survival compared with *A. fumigatus* \[[@C46]\]. Rapid germination of *A. fumigatus* within the macrophage comes at the cost of its increased vulnerability to host immunity. In contrast, *A. terreus* germinates at lower rates favouring its persistence. Our work highlights high proportions of bronchiectasis patients with both *A. fumigatus* and *A. terreus.* Moreover, such patients demonstrate greater exacerbations, suggestive that in combination these fungi have important clinical effects on distinct host pathways that worsen disease. As a consequence, assessment of fungal airway conidial burden is important in bronchiectasis.

While our work is novel, it does have limitations including its cross-sectional design. This is a consequence of our attempt to robustly match Asian and European cohorts within the study to address disease heterogeneity, a key issue in bronchiectasis research. In addition, we must consider the "generalisability" of our three participating countries in comparison to the wider Asian and European subcontinents, including the potential variation in aetiology for exacerbations, their management including bronchiectasis treatments, and geographic differences in climate, temperature and air quality. Epidemiological fungal studies have in fact illustrated species differences between countries even within the same subcontinent \[[@C32]\]. Furthermore, we included only a small group of nondiseased (healthy) individuals (all from Singapore) that precluded us from defining a "healthy" mycobiome clearly, which was not the primary aim of this work. Future studies, however, should focus on assessing the nondiseased lung mycobiome and include individuals from more than a single region to assess potential geographic variation. In addition, targeted amplicon sequencing, even through our parallel shotgun sequencing of ITS1 and ITS2, has lower resolution compared with the more costly and analytically challenging whole-genome shotgun metagenomics approach that provides superior speciation and functional annotation. We focused on *Aspergillus* as the predominant bronchiectasis-associated fungal pathogen; however, our mycobiome analysis suggests that other fungal genera may also have roles. Finally, when the CAMEB cohort was conceived, a decision was made to match across Singapore/Kuala Lumpur and Dundee based on age, sex and disease severity. This matching on total BSI rather than its specific components, including exacerbations, radiology or microbiology, limits our ability to perform more specific analyses. Our cohort enrolled predominantly severe patients with bronchiectasis with a relatively low number of patients with mild disease (BSI 0--4).

In conclusion, we have performed the first fungal profiling study in bronchiectasis to date using two "matched" cohorts across three countries. We illustrate high levels of airway fungi and key differences between cohorts. These data suggest that the role for fungi, and specifically *Aspergillus*, in bronchiectasis is significant and routine screening for *Aspergillus-*associated diseases should be considered for inclusion in future bronchiectasis guidelines. Screening may include skin testing, *Aspergillus*-associated specific IgE and *Aspergillus* specific IgG with potential follow-up immunological monitoring for those clinically affected. Our identified mycobiome profiles that relate to clinical disease should also be elucidated in future work.
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Supplementary figure E1. Measured levels of a) total IgE (IgE) b) *Aspergillus*-specific IgG and c) sputum galactomannan in patients classified immunologically as non-diseased (ND); *Aspergillus*-colonised (AC); *Aspergillus*-sensitised (AS); serological allergic bronchopulmonary aspergillosis (sABPA) and suspected chronic pulmonary aspergillosis (sCPA) (supplementary table E1). Broken lines indicate respective cut-offs indicating a positive test for each marker (total IgE: 100 IU⋅mL^-1^; *Aspergillus*-specific IgG: 5 AU⋅mL^-1^; galactomannan: OD~450~ 0.5). ERJ-00766-2018_Figure_E1

Supplementary figure E2. Genus-level rarefaction curve of sequenced ITS regions. The rarefaction curve represents, for each sample (n = 248; *i.e.* 238 bronchiectasis + 10 non-diseased), the number of genera identified given the fraction of sequencing data analysed (mean sequencing depth 3.29±0.184 million reads per sample). The relationship between the fraction of the sequencing data used ('down sampling rate' - *x*-axis) to identify the number of genera in the sample (*y*-axis) is illustrated. The more the fraction increases, the more genera identfied. Curve plateaus illustrate that enough data have been generated such that adequate recapitulation of the mycobiome can be assumed. ERJ-00766-2018_Figure_E2

Supplementary figure E3. Principal co-ordinate analysis (PCoA) plot of Bray--Curtis distances generated from genus-level abundances observed in the mycobiome. a) Beta-diversity, represented by Bray--Curtis distance, illustrates similarities among mycobiome profiles observed in bronchiectasis patients (n=238) which broadly classified patients into three groups. While the vast majority of mycobiome profiles fell within group 1 (green, *Candida*-dominant, n=202) two additional groups were also identified: group 2 (red, *Aspergillus*-dominant, n=23) and group 3 (blue, *Saccharomyces*-dominant, n=13). b) The relative abundance (%) of major discriminant taxa in each identified mycobiome group is indicated for all three groups. ERJ-00766-2018_Figure_E3
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